MCID: DMN002
MIFTS: 66

Dementia

Categories: Mental diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Dementia

MalaCards integrated aliases for Dementia:

Name: Dementia 12 74 53 29 54 6 42 15 39 71
Presenile Dementia 71
Dementias 15

Classifications:



External Ids:

Disease Ontology 12 DOID:1307
ICD9CM 34 290.8
ICD10 32 F02 F03
UMLS 71 C0011265 C0154319 C0497327

Summaries for Dementia

MedlinePlus : 42 What is dementia? Dementia is a loss of mental functions that is severe enough to affect your daily life and activities. These functions include Memory Language skills Visual perception (your ability to make sense of what you see) Problem solving Trouble with everyday tasks The ability to focus and pay attention It is normal to become a bit more forgetful as you age. But dementia is not a normal part of aging. It is a serious disorder which interferes with your daily life. What are the types of dementia? The most common types of dementia are known as neurodegenerative disorders. These are diseases in which the cells of the brain stop working or die. They include Alzheimer's disease, which is the most common form of dementia among older people. People with Alzheimer's have plaques and tangles in their brain. These are abnormal buildups of different proteins. Beta-amyloid protein clumps up and forms plaques in between your brain cells. Tau protein builds up and forms tangles inside the nerve cells of your brain. There is also a loss of connection between nerve cells in the brain. Lewy body dementia, which causes movement symptoms along with dementia. Lewy bodies are abnormal deposits of a protein in the brain. Frontotemporal disorders, which cause changes to certain parts of the brain: Changes in the frontal lobe lead to behavioral symptoms Changes in the temporal lobe lead to language and emotional disorders Vascular dementia, which involves changes to the brain's blood supply. It is often caused by a stroke or atherosclerosis (hardening of the arteries) in the brain. Mixed dementia, which is a combination of two or more types of dementia. For example, some people have both Alzheimer's disease and vascular dementia. Other conditions can cause dementia or dementia-like symptoms, including Creutzfeldt-Jakob disease, a rare brain disorder Huntington's disease, an inherited, progressive brain disease Chronic traumatic encephalopathy (CTE), caused by repeated traumatic brain injury HIV-associated dementia (HAD) Who is at risk for dementia? Certain factors can raise your risk for developing dementia, including Aging. This is the biggest risk factor for dementia. Smoking Uncontrolled diabetes High blood pressure Drinking too much alcohol Having close family members who have dementia What are the symptoms of dementia? The symptoms of dementia can vary, depending on which parts of the brain are affected. Often, forgetfulness is the first symptom. Dementia also causes problems with the ability to think, problem solve, and reason. For example, people with dementia may Get lost in a familiar neighborhood Use unusual words to refer to familiar objects Forget the name of a close family member or friend Forget old memories Need help doing tasks that they used to do by themselves Some people with dementia cannot control their emotions and their personalities may change. They may become apathetic, meaning that they are no longer interested in normal daily activities or events. They may lose their inhibitions and stop caring about other peoples' feelings. Certain types of dementia can also cause problems with balance and movement. The stages of dementia range from mild to severe. In the mildest stage, it is just beginning to affect a person's functioning. In the most severe stage, the person is completely dependent on others for care. How is dementia diagnosed? To make a diagnosis, your health care provider Will ask about your medical history Will do a physical exam Will check your thinking, memory, and language abilities May do tests, such as blood tests, genetic tests, and brain scans May do a mental health evaluation to see whether a mental disorder is contributing to your symptoms What are the treatments for dementia? There is no cure for most types of dementia, including Alzheimer's disease and Lewy body dementia. Treatments may help to maintain mental function longer, manage behavioral symptoms, and slow down the symptoms of disease. They may include Medicines may temporarily improve memory and thinking or slow down their decline. They only work in some people. Other medicines can treat symptoms such as anxiety, depression, sleep problems, and muscle stiffness. Some of these medicines can cause strong side effects in people with dementia. It is important to talk to your health care provider about which medicines will be safe for you. Occupational therapy to help find ways to more easily do everyday activities Speech therapy to help with swallowing difficulties and trouble speaking loudly and clearly Mental health counseling to help people with dementia and their families learn how to manage difficult emotions and behaviors. It can also help them plan for the future. Music or art therapy to reduce anxiety and improve well-being Can dementia be prevented? Researchers have not found a proven way to prevent dementia. Living a healthy lifestyle might influence some of your risk factors for dementia.

MalaCards based summary : Dementia, also known as presenile dementia, is related to frontotemporal dementia and dementia, lewy body, and has symptoms including seizures, tremor and back pain. An important gene associated with Dementia is MAPT (Microtubule Associated Protein Tau), and among its related pathways/superpathways are Parkinson disease and Neuroscience. The drugs Rasagiline and Progesterone have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and heart, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 A cognitive disorder resulting from a loss of brain function affecting memory, thinking, language, judgement and behavior.

NINDS : 53 Dementia is the loss of cognitive functioning—the ability to think, remember, problem solve or reason—to such an extent that it interferes with a person’s daily life and activities. Dementia ranges in severity from the mildest stage, when it is just beginning to affect a person’s functioning, to the most severe stage, when the person must depend completely on others for basic activities of daily living. Functions affected include memory, language skills, visual perception, problem solving, self-management, and the ability to focus and pay attention. Some people with dementia cannot control their emotions, and their personalities may change. Signs and symptoms of dementia result when once-healthy neurons (nerve cells) in the brain stop working, lose connections with other brain cells, and die. While everyone loses some neurons as they age, people with dementia experience far greater loss. Unlike dementia, age-related memory loss isn’t disabling. While dementia is more common with advanced age (as many as half of all people age 85 or older may have some form of dementia), it is not normal part of aging. Many people live into their 90s and beyond without any signs of dementia. The causes of dementia can vary. Many people with dementia have both Alzheimer’s disease and one or more closely related disorders that share brain scanning or clinical (and sometimes both) features with Alzheimer’s disease. When a person is affected by more than one dementia disorder, the dementia can be referred to as a mixed dementia. Some people may have mixed dementia caused by Alzheimer’s-related neurodegenerative processes, vascular disease-related processes, or another neurodegenerative condition. Many other conditions such as Creutzfeldt-Jakob disease, Huntington’s Disease, and chronic traumatic encephalopathy can cause dementia or dementia-like symptoms. Risk factors for dementia include advancing age, stroke, high blood pressure, poorly controlled diabetes, and a thickening of blood vessel walls (atherosclerosis). Other dementias include frontotemporal disorders, vascular dementia, and Lewy body dementia.

Wikipedia : 74 Dementia is a broad category of brain diseases that cause a long-term and often gradual decrease in the... more...

Related Diseases for Dementia

Diseases in the Dementia family:

Rare Dementia Infectious Disease with Dementia

Diseases related to Dementia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1441)
# Related Disease Score Top Affiliating Genes
1 frontotemporal dementia 35.6 VCP UBQLN2 TARDBP SQSTM1 SNCB SNCA
2 dementia, lewy body 35.6 VCP TARDBP SNCB SNCA PSEN1 PARK7
3 frontotemporal dementia and/or amyotrophic lateral sclerosis 1 35.5 VCP UBQLN2 TARDBP SQSTM1 SNCA PSEN1
4 vascular dementia 35.4 PSEN1 MAPT APP APOE
5 inclusion body myopathy with paget disease of bone and frontotemporal dementia 35.3 VCP UBQLN2 TARDBP SQSTM1 FUS CHMP2B
6 amyotrophic lateral sclerosis-parkinsonism/dementia complex 1 35.3 TRPM7 TARDBP SNCB SNCA PARK7 MAPT
7 semantic dementia 35.3 TARDBP PSEN1 MAPT GRN CHMP2B C9orf72
8 frontotemporal dementia, chromosome 3-linked 35.3 VCP TARDBP MAPT GRN FUS CHMP2B
9 alzheimer disease 35.1 VCP TARDBP SQSTM1 SNCB SNCA PSEN1
10 frontotemporal dementia and/or amyotrophic lateral sclerosis 3 35.1 TARDBP SQSTM1 C9orf72
11 pick disease of brain 34.9 VCP UBQLN2 TARDBP SQSTM1 SNCA PSEN1
12 amyotrophic lateral sclerosis, juvenile, with dementia 34.8 TARDBP SNCB
13 frontotemporal dementia and/or amyotrophic lateral sclerosis 2 34.7 CHCHD10 C9orf72
14 amyotrophic lateral sclerosis 10 with or without frontotemporal dementia 34.7 UBQLN2 TARDBP FUS CHMP2B C9orf72
15 polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy 1 34.7 TYROBP PSEN1 GRN APP APOE
16 frontotemporal lobar degeneration with tdp43 inclusions, grn-related 34.6 MAPT GRN
17 amyotrophic lateral sclerosis 1 34.5 VCP UBQLN2 TARDBP SQSTM1 SNCA PSEN1
18 cerebral amyloid angiopathy, itm2b-related, 1 34.5 PSEN1 ITM2B APP
19 binswanger's disease 34.4 MAPT APP APOE
20 gerstmann-straussler disease 34.4 SNCA PSEN1 MAPT APP
21 kohlschutter-tonz syndrome 34.4 TYROBP PSEN1 MAPT APP
22 leukoencephalopathy, hereditary diffuse, with spheroids 34.3 TYROBP SNCA MAPT APP
23 creutzfeldt-jakob disease 34.2 SNCA PARK7 MAPT APP APOE
24 prion disease 34.1 TARDBP SNCA PSEN1 MAPT APP APOE
25 cerebral amyloid angiopathy, app-related 34.0 PSEN1 MAPT ITM2B APP APOE
26 supranuclear palsy, progressive, 1 33.9 VCP TARDBP SNCA PSEN1 PARK7 MAPT
27 aphasia 33.8 VCP TARDBP SNCB SNCA PSEN1 MAPT
28 parkinson disease, late-onset 33.8 VCP SQSTM1 SNCB SNCA PSEN1 PARK7
29 normal pressure hydrocephalus 33.6 PSEN1 MAPT C9orf72 APP APOE
30 cerebral amyloid angiopathy, cst3-related 33.6 TARDBP SNCA PSEN1 MAPT ITM2B APP
31 amyotrophic lateral sclerosis type 14 33.5 VCP UBQLN2 FUS CHMP2B C9orf72
32 multisystem proteinopathy 33.5 VCP UBQLN2 TARDBP SQSTM1 FUS C9orf72
33 huntington disease 33.5 SQSTM1 SNCA PSEN1 MAPT APP
34 fatal familial insomnia 33.4 SNCA MAPT APP
35 apraxia 33.4 PSEN1 MAPT GRN C9orf72 APOE
36 progressive non-fluent aphasia 33.4 VCP PSEN1 MAPT GRN CHMP2B C9orf72
37 corticobasal degeneration 33.4 TARDBP MAPT GBA
38 multiple system atrophy 1 33.3 SQSTM1 SNCB SNCA PARK7 MAPT
39 neurodegeneration with brain iron accumulation 33.2 SNCB SNCA PARK7 MAPT
40 alzheimer disease 2 33.1 PSEN1 MAPT APP APOE
41 posterior cortical atrophy 33.1 MAPT APOE
42 basal ganglia calcification 33.1 TYROBP PSEN1 MAPT APP
43 parkinson disease 1, autosomal dominant 33.1 SNCA GBA
44 machado-joseph disease 33.1 VCP TARDBP SNCA APOE
45 spinocerebellar ataxia 2 33.0 UBQLN2 TARDBP FUS C9orf72
46 amyotrophic lateral sclerosis type 15 33.0 UBQLN2 CHMP2B C9orf72
47 down syndrome 32.9 PSEN1 MAPT APP APOE
48 perry syndrome 32.9 VCP TARDBP SNCA MAPT GRN CHMP2B
49 amyotrophic lateral sclerosis type 6 32.8 UBQLN2 TARDBP FUS CHMP2B C9orf72
50 alzheimer disease 18 32.8 SNCA APP

Graphical network of the top 20 diseases related to Dementia:



Diseases related to Dementia

Symptoms & Phenotypes for Dementia

UMLS symptoms related to Dementia:


seizures, tremor, back pain, angina pectoris, headache, syncope, pain, chronic pain, sciatica, vertigo/dizziness, equilibration disorder, sleeplessness

GenomeRNAi Phenotypes related to Dementia according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00221-A-1 9.74 TRPM7 TYROBP
2 Decreased viability GR00221-A-2 9.74 TRPM7
3 Decreased viability GR00221-A-4 9.74 FUS TRPM7
4 Decreased viability GR00231-A 9.74 SQSTM1
5 Decreased viability GR00249-S 9.74 GBA MAPT PARK7 PSEN1 SNCA UBQLN2
6 Decreased viability GR00381-A-1 9.74 SQSTM1 VCP
7 Decreased viability GR00386-A-1 9.74 APOE CHMP2B GRN UBQLN2
8 Decreased viability GR00402-S-2 9.74 CHCHD10 GBA GRN MAPT PARK7 SQSTM1

MGI Mouse Phenotypes related to Dementia:

45 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.4 APOE APP C9orf72 CHCHD10 GBA GRN
2 growth/size/body region MP:0005378 10.36 APOE APP C9orf72 CHCHD10 GBA GRN
3 cellular MP:0005384 10.35 APOE APP C9orf72 CHCHD10 GBA GRN
4 homeostasis/metabolism MP:0005376 10.28 APOE APP C9orf72 CHCHD10 GBA GRN
5 hematopoietic system MP:0005397 10.25 APOE APP C9orf72 CHCHD10 GBA GRN
6 immune system MP:0005387 10.21 APOE APP C9orf72 CHCHD10 GBA GRN
7 mortality/aging MP:0010768 10.13 APOE APP C9orf72 CHCHD10 CHMP2B GBA
8 nervous system MP:0003631 10.11 APOE APP C9orf72 CHCHD10 CHMP2B GBA
9 integument MP:0010771 10.06 APOE APP C9orf72 GBA GRN MAPT
10 no phenotypic analysis MP:0003012 9.61 APOE APP C9orf72 GRN ITM2B MAPT
11 skeleton MP:0005390 9.32 APOE CHCHD10 GBA PSEN1 SNCA SNCB

Drugs & Therapeutics for Dementia

Drugs for Dementia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 795)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Rasagiline Approved Phase 4 136236-51-6 3052776
2
Progesterone Approved, Vet_approved Phase 4 57-83-0 5994
3
Methylcobalamin Approved, Investigational Phase 4 13422-55-4
4
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
5
Nimodipine Approved, Investigational Phase 4 66085-59-4 4497
6
Haloperidol Approved Phase 4 52-86-8 3559
7
Hydrocodone Approved, Illicit, Investigational Phase 4 125-29-1 5284569
8
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
9
Ethanol Approved Phase 4 64-17-5 702
10
Clozapine Approved Phase 4 5786-21-0 2818
11
Enalapril Approved, Vet_approved Phase 4 75847-73-3 40466924 5362032
12
Enalaprilat Approved Phase 4 76420-72-9 6917719
13
Levetiracetam Approved Phase 4 102767-28-2 441341
14
Lisinopril Approved, Investigational Phase 4 76547-98-3, 83915-83-7 5362119
15
Candesartan cilexetil Approved Phase 4 145040-37-5 2540
16
Dextroamphetamine Approved, Illicit Phase 4 51-64-9 5826
17
Diazepam Approved, Illicit, Investigational, Vet_approved Phase 4 439-14-5 3016
18
Ertapenem Approved, Investigational Phase 4 153832-46-3 150610
19
Carvedilol Approved, Investigational Phase 4 72956-09-3 2585
20
Doxazosin Approved Phase 4 74191-85-8 3157
21
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
22
Lercanidipine Approved, Investigational Phase 4 100427-26-7 65866
23
Valsartan Approved, Investigational Phase 4 137862-53-4 60846
24
Manidipine Approved, Investigational Phase 4 89226-50-6
25
Ramipril Approved Phase 4 87333-19-5 5362129
26
Atenolol Approved Phase 4 29122-68-7 2249
27
Quinapril Approved, Investigational Phase 4 85441-61-8 54892
28
Infliximab Approved Phase 4 170277-31-3
29
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
30
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
31
Angiotensin II Approved, Investigational Phase 4 4474-91-3, 11128-99-7, 68521-88-0 172198
32
Losartan Approved Phase 4 114798-26-4 3961
33
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 158781 130881
34
Naproxen Approved, Vet_approved Phase 4 22204-53-1 1302 156391
35
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
36
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
37
Ibuprofen Approved Phase 4 15687-27-1 3672
38
Formaldehyde Approved, Vet_approved Phase 4 50-00-0 712
39
Mirabegron Approved Phase 4 223673-61-8 9865528
40
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
41
Pravastatin Approved Phase 4 81093-37-0 54687
42
acetic acid Approved Phase 4 64-19-7 176
43
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
44
Levobupivacaine Approved, Investigational Phase 4 27262-47-1 92253
45
Opium Approved, Illicit Phase 4 8008-60-4
46
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
47
Clarithromycin Approved Phase 4 81103-11-9 84029
48
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
49
Esomeprazole Approved, Investigational Phase 4 161796-78-7, 119141-88-7, 161973-10-0 9568614 4594
50
Benazepril Approved, Investigational Phase 4 86541-75-5 5362124

Interventional clinical trials:

(show top 50) (show all 3138)
# Name Status NCT ID Phase Drugs
1 Exploratory Study to Assess the Efficacy of Escitalopram Versus Placebo in the Treatment of Depressive Syndrome in Alzheimer’s Disease, Vascular Dementia and Mixed Vascular and Alzheimer’s Dementia Unknown status NCT00229333 Phase 4 Escitalopram
2 Dopaminergic Enhancement of Learning and Memory (LL_001, Project on Dementia/MCI) Unknown status NCT00306124 Phase 4 Levodopa
3 Pragmatic Randomized Control Trial of Memantine For Agitation In Dementia Unknown status NCT00371059 Phase 4 Memantine;Placebo
4 A Randomised Placebo Controlled Trial of a Cholinesterase Inhibitor in the Management of Agitation in Dementia That is Unresponsive to a Psychological Intervention Unknown status NCT00142324 Phase 4 Donepezil
5 Open Label Trial of Rivastigmine Patch in Subjects With Mild to Moderate Stage Alzheimer's Disease Having Coexisting Small Vessel Cerebrovascular Disease Unknown status NCT02444637 Phase 4 Rivastigmine
6 Cognitive Dysfunction in PD: Pathophysiology and Potential Treatments, a Pilot Study Unknown status NCT01340885 Phase 4 Strattera;Exelon
7 Huperzine-A for Cognitive Dysfunction and Functional Status in Schizophrenia Unknown status NCT01012830 Phase 4 Huperzine A
8 A 24-Week Pilot, Double-Blind, Randomized, Parallel, Placebo-Controlled Study of Memantine and Constraint-Induced Language Therapy in Chronic Poststroke Aphasia:Correlation With Cognitive Evoked Potentials During Recovery. Unknown status NCT00196703 Phase 4 memantine
9 Memantine Treatment in Alzheimer's Disease Patients Stratified With Behavioral and Psychological Symptoms of Dementia (BPSD) Symptoms and Cognitive Severity: A Multi-center, Open-label, Parallel-group and Prospective Clinical Study Unknown status NCT03168997 Phase 4 Memantine Hydrochloride
10 Transcranial Magnetic Stimulation for Apathy in Mild Cognitive Impairment:Pilot Study Unknown status NCT02190019 Phase 4
11 Treatment With Acetyl-Choline Esterase Inhibitors in Children With Autism Unknown status NCT01098383 Phase 4 Acetyl-Choline Esterase Inhibitors and Choline supplements;Indistinguishable placebo tablets, matching both donepezil and choline
12 Phase IV Study of General Clinical Research Center Of the Jinan Mental Hospital(TAIWAN) Unknown status NCT00626613 Phase 4 Risperdal,reminyl
13 Insulin Resistance and Mild Cognitive Impairment (MCI) in Older Chinese Adults With Pre-Diabetes and Diabetes: Cognitive Effects of Lifestyle Intervention and Metformin Treatment in a Randomized Controlled Trial Unknown status NCT02409238 Phase 4 Metformin
14 Donepezil and Memantine in Moderate to Severe Alzheimer's Disease Unknown status NCT00866060 Phase 4 Memantine;Donepezil;Placebo donepezil;Placebo memantine
15 Effect of the Stage Specific Cognitive Intervention Program on Functional Cortical Activation in Alzheimer's Disease Unknown status NCT01329601 Phase 4
16 The Effects of Rasagiline on Cognitive Deficits Associated With Parkinson's Disease: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study Over 3 Months Unknown status NCT00696215 Phase 4 placebo;rasagiline
17 Delirium: Is Prophylactic Drug Therapy Useful in High Risk Patients as Defined by the Delirium Risk Prediction Model? Unknown status NCT03199950 Phase 4 Haloperidol;Placebo Oral Tablet
18 A 12 Week, Open Label, Efficacy and Safety Study of Desvenlafaxine in the Treatment of Vascular Depression Unknown status NCT01974934 Phase 4 Desvenlafaxine Succinate
19 Study Effects of Ginkgo Biloba Extract on Endothelial Cell Function and Genetic Effects on the Response to Ginkgo Biloba Extract in Diabetic Patients With Stable Coronary Artery Disease Unknown status NCT01038050 Phase 4 Ginkgo Biloba Extract (GBE)
20 CHADSS: Chagas Disease Scan Study Unknown status NCT01650792 Phase 4 Aspirin
21 Does Discontinuation of Aspirin Treatment Following Head Trauma Decrease the Incidence of Chronic Subdural Hematoma? Unknown status NCT01470040 Phase 4 discontinuation of aspirin therapy;continuation of aspirin therapy
22 Serotonergic Function and Behavioural and Psychological Symptoms of Frontotemporal Dementia Completed NCT00376051 Phase 4 Citalopram
23 A Post-Marketing Clinical Study of Aricept in Patients With Dementia With Lewy Bodies (DLB) Completed NCT02345213 Phase 4 E2020;Placebo
24 A Randomised, Double-blind, Placebo-controlled, 6-month Study of the Efficacy and Safety of Memantine in Patients With Parkinson's Disease Dementia or Dementia With Lewy Bodies Completed NCT00855686 Phase 4 Memantine;Placebo
25 Cilostazol Verse Asprin for Vascular Dementia in Poststroke Patients With White Completed NCT00847860 Phase 4 Cilostazol;Aspirin
26 Interventional, Randomised, Double-blind, Study to Evaluate the Safety and Tolerability of Once Daily Versus Twice Daily Memantine Treatment in Patients With Dementia of Alzheimer's Type and MMSE Range 5 - 18 Completed NCT02553928 Phase 4 Memantine (once daily);Memantine (twice daily)
27 The Role of Methycobalamin in Early Dementia Patients With Vitamin B12 Deficiency and Hyperhomocysteinaemia. Completed NCT00165711 Phase 4 Mecobalamin
28 Treatment of Agitation/Psychosis in Dementia/Parkinsonism (TAP/DAP) Completed NCT00043849 Phase 4 Quetiapine
29 A Prospective, Randomized, Multi-Center, Double-Blind, 26 Week, Placebo-Controlled Trial of Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia Completed NCT00545974 Phase 4 memantine;Placebo pill
30 Discontinuation of Antipsychotics and Antidepressants Among Patients With Dementia and BPSD Living in Nursing Homes - an Open Study. Completed NCT00433121 Phase 4 Risperidone;Olanzapine;Haloperidole;Quetiapin;Escitalopram;Citalopram;Sertralin
31 Discontinuation of Antipsychotics and Antidepressants Among Patients With Dementia and BPSD Living in Nursing Homes - a 24 Weeks Double Blind RCT. Completed NCT00594269 Phase 4 Risperidone;Escitalopram;Citalopram;Sertraline;Paroxetine
32 Efficacy of Pain Treatment on Depression in Patients With Dementia. A Randomized Clinical Trial. Completed NCT02267057 Phase 4 Paracetamol;Buprenorphine;Paracetamol placebo;Buprenorphine placebo
33 An Open Label Study on the Efficacy and Safety of Donepezil Hydrochloride (Aricept) in Vascular Dementia Completed NCT00165763 Phase 4 donepezil hydrochloride (Aricept)
34 Can Oral Vitamin B12 and Folate Supplementation Preserve Cognitive Function of Patients With Early Dementia? Completed NCT00164970 Phase 4
35 A Randomized Placebo-controlled Trial Evaluating the Effect of Melatonin on Sleep Quality in Patients With Dementia Completed NCT03066518 Phase 4 Melatonin 5 mg
36 Study on the Efficacy of Speed-Feedback Therapy for Elderly People With Dementia: a Randomized Controlled Trial Completed NCT00450047 Phase 4
37 Efficacy and Tolerance of EGb 761® 120mg Two Times a Day on Dementia of Alzheimer Type's Onset in Patients Suffering From Memory Complaints. A Randomised, Double-blind, Multicentre, Parallel Groups, Placebo Controlled Phase IIIb/IV Study in Elderly Over 70 Completed NCT00276510 Phase 4 EGb 761® (Tanakan®)
38 An Open-Label Exploratory Study With Memantine: Assessment of Selected Measures of Volumetric MRI and Cognition in Patients With Moderate Dementia of the Alzheimer's Type Completed NCT00334906 Phase 4 memantine HCl
39 Cilostazol Augmentation Study In Dementia (CASID): A Randomized, Placebo-controlled Pilot Study to Compare the Efficacy Between Donepezil Monotherapy and Cilostazol Augmentation Therapy in Alzheimer's Disease Patients With Subcortical White Matter Hyperintensities Completed NCT01409564 Phase 4 Cilostazol;Placebo
40 The Use of Galantamine (Reminyl ER) in Patients With MIXed Dementia: Effects on Cognition and Quality of Life Completed NCT00814658 Phase 4 Galantamine;Nimodipine;Placebo
41 Corticolimbic Degeneration and Treatment of Dementia Completed NCT00768261 Phase 4 Memantine (Namenda®);Donepezil (Aricept®)
42 Low-Dose Opiate Therapy for Discomfort in Dementia (L-DOT) Completed NCT00385684 Phase 4 hydrocodone/APAP w placebo PRN;hydrocodone/APAP;placebo with hydrocodone/APAP PRN
43 Post Marketing Study of Escitalopram Versus Risperidone for the Treatment of Behavioral and Psychological Symptoms Amongst Alzheimer's Disease Patients Completed NCT01119638 Phase 4 Escitalopram;Risperidone
44 Rivastigmine Patch Effect on the Post-operative Delirium Limited to Femur Neck Fracture Operation in Patients at Risk of Dementia. Completed NCT02413554 Phase 4 Rivastigmine patch
45 Donepezil for Dementia in Parkinson's Disease: A Randomized, Double Blinded Placebo Controlled Crossover Trial Completed NCT00030979 Phase 4 Donepezil
46 Escitalopram in the Treatment of Patients With Agitated Dementia Completed NCT00260624 Phase 4 Escitalopram (Lexapro)
47 Randomized Comparison of Monotherapy (Risperidone, Quetiapine, or Olanzapine) Versus Combination Therapy (Risperidone, Quetiapine, or Olanzapine + Divalproex)in the Management of Dementia With Agitation: A Pilot Comparison of Two Standard Therapies Completed NCT00208819 Phase 4 risperidone;quetiapine;olanzapine;divalproex
48 A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Donepezil Hydrochloride (E2020) in Patients With Dementia Associated With Cerebrovascular Disease Completed NCT02660983 Phase 4 Donepezil hydrochloride;Donepezil matching placebo;Donepezil hydrochloride
49 A Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of 20 ml Cerebrolysin in Patients With Vascular Dementia Completed NCT00947531 Phase 4 Cerebrolysin;0.9% Saline Solution
50 A 52-week, Prospective, Multi-center, Open-label Study to Assess the Tolerability of Rivastigmine Before and After Switching From Oral Formulation to Transdermal Patch in Patients With Alzheimer's Dementia in a Controlled Titration Schedule Completed NCT01585272 Phase 4 ENA713

Search NIH Clinical Center for Dementia

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Citalopram
Citalopram hydrobromide
Prochlorperazine
Prochlorperazine Edisylate Salt
Prochlorperazine Maleate
Risperidone

Genetic Tests for Dementia

Genetic tests related to Dementia:

# Genetic test Affiliating Genes
1 Dementia 29

Anatomical Context for Dementia

MalaCards organs/tissues related to Dementia:

40
Brain, Testes, Heart, Cortex, Kidney, Temporal Lobe, Eye

Publications for Dementia

Articles related to Dementia:

(show top 50) (show all 31224)
# Title Authors PMID Year
1
Fourth Canadian Consensus Conference on the Diagnosis and Treatment of Dementia: recommendations for family physicians. 61 6
24829003 2014
2
Brain 18F-FDG-PET: Utility in the Diagnosis of Dementia and Epilepsy. 42 61
32147984 2020
3
Cognitive training interventions for dementia and mild cognitive impairment in Parkinson's disease. 61 42
32101639 2020
4
Association of Blood Pressure Lowering With Incident Dementia or Cognitive Impairment: A Systematic Review and Meta-analysis. 42
32427305 2020
5
Diabetes synergistically exacerbates poststroke dementia and tau abnormality in brain. 61 54
20398714 2010
6
The presence of sodium dodecyl sulphate-stable Abeta dimers is strongly associated with Alzheimer-type dementia. 54 61
20403962 2010
7
Inclusion body myopathy, Paget's disease of the bone and fronto-temporal dementia: a disorder of autophagy. 54 61
20410287 2010
8
Donepezil, an acetylcholinesterase inhibitor against Alzheimer's dementia, promotes angiogenesis in an ischemic hindlimb model. 54 61
19962381 2010
9
Odor identification impairment in carriers of ApoE-varepsilon4 is independent of clinical dementia. 54 61
18619712 2010
10
Will testing for apolipoprotein E assist in tailoring dementia risk reduction? A review. 54 61
19720080 2010
11
Neurodegenerative dementia and parkinsonism. 61 54
20082052 2010
12
Intrathecal IgG synthesis in patients with alterations in the neurochemical dementia diagnostics. 61 54
20308786 2010
13
[Frontotemporal dementia in association with a family history of dementia and ApoE polymorphism]. 61 54
19629426 2010
14
New laboratory markers in diagnosis of alzheimer dementia. 61 54
19589198 2009
15
Cerebrospinal hypocretin, daytime sleepiness and sleep architecture in Parkinson's disease dementia. 54 61
19858078 2009
16
Decreased serum brain-derived neurotrophic factor levels in elderly korean with dementia. 54 61
20140129 2009
17
The morbid anatomy of dementia in Parkinson's disease. 61 54
19820956 2009
18
A case of dementia with PRNP D178Ncis-129M and no insomnia. 61 54
19571725 2009
19
Serotonergic system genes in psychosis of Alzheimer dementia: meta-analysis. 61 54
19910872 2009
20
Alterations in trace elements and oxidative stress in uremic patients with dementia. 54 61
19242659 2009
21
Paraoxonase activity and dementia. 61 54
19268306 2009
22
Mitochondrial disorders, cognitive impairment and dementia. 54 61
19268975 2009
23
Recent insights into the molecular genetics of dementia. 54 61
19640594 2009
24
Cognitive activities delay onset of memory decline in persons who develop dementia. 61 54
19652139 2009
25
Association between BDNF Val66Met polymorphism and Alzheimer disease, dementia with Lewy bodies, and Pick disease. 61 54
19812463 2009
26
[Genetic basis for dementia]. 61 54
19507496 2009
27
Potential anti-dementia agents in traditional Chinese medicine. 61 54
19634342 2009
28
Cerebrospinal fluid beta-glucocerebrosidase activity is reduced in Dementia with Lewy Bodies. 61 54
19303930 2009
29
Association of glucocerebrosidase mutations with dementia with lewy bodies. 54 61
19433657 2009
30
Plasma progranulin levels predict progranulin mutation status in frontotemporal dementia patients and asymptomatic family members. 54 61
19158106 2009
31
Apolipoprotein E genotype as a risk factor for susceptibility to and dementia in Parkinson's disease. 54 61
19308307 2009
32
Mortality, dementia, and apolipoprotein E genotype in elderly white women in the United States. 54 61
19207139 2009
33
Ethnic disparities in the treatment of dementia in veterans. 61 54
19690417 2009
34
Dopamine transporter single photon emission computerized tomography in the diagnosis of dementia with Lewy bodies. 54 61
19877236 2009
35
Cerebrospinal fluid alpha-synuclein does not discriminate between dementia disorders. 54 61
19221426 2009
36
Choline acetyltransferase activity in vascular dementia and stroke. 61 54
19776575 2009
37
Dementia in Parkinson's disease. 54 61
18989112 2008
38
[Novel neuroimaging perspectives in the diagnosis of dementia]. 54 61
18830576 2008
39
Association of GSK3B with Alzheimer disease and frontotemporal dementia. 54 61
18852354 2008
40
Lewy body dementia and Parkinson's disease with dementia. 54 61
18787881 2008
41
Diagnostic performance of a CSF-biomarker panel in autopsy-confirmed dementia. 54 61
17428581 2008
42
Matrix metalloproteinase 3 haplotypes and dementia and Alzheimer's disease. The Rotterdam Study. 61 54
17316907 2008
43
The impact of apolipoprotein E on dementia in persons with Down's syndrome. 54 61
17250929 2008
44
Novel PRNP mutation in a patient with a slow progressive dementia syndrome. 54 61
18443555 2008
45
Quantitative analysis of transthyretin, tau and amyloid-beta in patients with dementia. 54 61
18525124 2008
46
Recent advances in the genetics of dementia with lewy bodies. 61 54
18541113 2008
47
Glucocorticoid receptor variant and risk of dementia and white matter lesions. 61 54
17184882 2008
48
Patients homozygous and heterozygous for SNCA duplication in a family with parkinsonism and dementia. 61 54
18413475 2008
49
Alpha-synuclein promoter haplotypes and dementia in Parkinson's disease. 61 54
17918232 2008
50
Neuropsychological characteristics of dementia with Lewy bodies and Parkinson's disease with dementia: differentiation, early detection, and implications for "mild cognitive impairment" and biomarkers. 61 54
18322801 2008